Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
India sales grew 23.5% YoY with consolidation of Wockhardt products
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Financial support is being provided as a grant from the Government of India
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The agreement will help ensure wider reach and access to patients in India
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Subscribe To Our Newsletter & Stay Updated
